adMare BioInnovations use their scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent — they re-invest their returns back into the Canadian industry to ensure it is sustained for the long-term.
Part of the Bill and Melinda Gates Foundation, AMG consultants help foster commitment to advancing global health and development goals.
Animol Discovery are accelerating the identification of innovative medicines for unmet needs in animals by using a unique approach to small molecule discovery and development. They combine genomics analysis, billions of molecules from DNA-encoded libraries, artificial intelligence/machine learning and computational chemistry technologies to identify more effective and safer pharmaceuticals.
Apollo Therapeutics is a biopharmaceutical company, rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. They identify and develop pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options. Their team combines ‘drug hunters’ and deep subject matter experts who together are building an expansive and de-risked portfolio in oncology, major inflammatory disorders, and rare diseases.
Arrakis Therapeutics are on an expedition to unlock the biology of RNA to discover new medicines for millions of people. They are focused on ways to target the RNA lifecycle to find new points of therapeutic intervention. Their drug discovery tools have re‑engineered the pharmaceutical industry’s small-molecule drug discovery toolkit to be directed at RNA. The company is headquartered in Waltham, MA.
AstronauTx focus on novel approaches to treating neurodegenerative diseases. They have a unique portfolio of small-molecule therapeutics to both improve symptoms and modify disease.
Augustine Therapeutics is a spin-off of VIB and KU Leuven, focused on early drug discovery. The company is building a portfolio of first-in-class therapies for rare neuromuscular neurodegenerative diseases focused on the neuroprotective potential of small-molecule HDAC6 inhibitors.
BIAL is an innovative pharmaceutical company. Dedicated to discovering, developing and commercializing medicines, they are committed to improve people’s lives worldwide.
The Blavatnik Center for drug discovery is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design. The (BCDD) provides a state-of-the-art R&D environment and academic platform in the relevant fields of early stage drug discovery.
Captor Therapeutics is a biopharmaceutical company leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough therapeutics for high unmet medical needs. TPD revolutionizes drug development by targeting “undruggable” molecular targets and providing new treatment options for diseases with unmet medical needs. They are based in Basel, Switzerland, and Wroclaw, Poland, and develop therapeutics for severe conditions like cancer and autoimmune diseases.
Cerevance is focused on the development of treatments for central nervous system (CNS) disorders. They are generating a catalog of the most promising targets for next generation treatments capable of transforming the lives of patients affected by CNS disorders. A team of world leading scientists and drug developers are utilizing the company’s proprietary NETSseq platform and advanced machine learning techniques to identify previously undiscovered gene expression profiles in select cell types.
Delphia are reimagining the treatment of cancer. Their team is focused on progressing novel science from concept through to approved medicines to improve the lives of those living with cancer.
DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumours.
The Drugs for the Neglected Disease Initiative (DNDi) develop life-saving medicines for people with neglected diseases around the world. Since 2003, the Drugs for Neglected Diseases initiative has developed 13 treatments for 6 deadly diseases, innovating to save lives.
DongBang FTL business includes synthetic APIs (Active Pharmaceutical Ingredients), natural APIs, health functional foods, and finished pharmaceutical products. They have proven ability to produce the highest quality pharmaceuticals through certifications such as EU-GMP (France ANSM), Japan GMP (PDMA), and Australia GMP (TGA).
Evotec is an R&D biotech that offers accelerating, high value pipeline co-creation partnerships and CRO/CDMO services – for R&D programs from disease understanding towards IND, Phase 1, and beyond. They use industrialized, AI-powered proprietary R&D platforms such as PanOmics and iPSC technologies and AI and continuous manufacturing technology to allow better access to high-quality biotherapeutics.
FMC is an agricultural sciences company that advances farming through innovative and sustainable crop protection technologies. FMC operates in more than 50 companies worldwide with a robust discovery pipeline to bring innovative solutions to growers worldwide.
FundaMental Pharma GmbH is a neuroscience company with portfolio at the preclinical stage, which was spun out of the Department of Neurobiology at Heidelberg University, Germany.
Grünenthal is a global leader in pain management and related diseases. They are a science-based, privately-owned pharmaceutical company, with a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.
The Helmholtz Centre for Infection Research (HZI) investigate the mechanisms of infectious diseases and the defence against them towards medical and pharmaceutical application. They believe that understanding the mechanisms of infections then contributes to the development of novel, patient-tailored solutions for diagnosis, prevention, treatment as well as surveillance and control of infectious diseases.
Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation. Their lead product is a first-in-class, small molecule inhibitor of Transducin Beta-like Protein 1 (TBL1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.
Lgenia believe that new medicines begin their trek to patients right at the very start of discovery. The very best, highest quality medicines should be affordable and accessible to all patients and it is their mission to discover new medications for debilitating diseases and make them affordable to all.
The team at LoQus Therapeutics take a structure-based approach to mismatch repair drug discovery, investigating small molecule drugs that could stop DNA instability and therefore slow neurodegeneration.
The Medicines for Malaria Venture (MMV) aim to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
New Frontier Bio is a consumer health company identifying, optimizing, and commercializing natural compounds for human health and longevity by utilizing biopharma and biotech principles. They focus on new molecular combinations inspired by nature that work synergistically to reveal their full biological potential.
NovAliX is a drug discovery-focused CRO. Their medicinal chemistry experts integrate solid expertise in biophysics, chemistry, computational chemistry and molecular modelling to support drug discovery programs, from assessment of target to lead optimization.
Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine. They have designed and generated large DNA encoded libraries (DELs) and arrayed libraries of non-degrading molecular glues (RapaGlues™) that are designed on a FKBP-binding macrocyclic peptide platform with the aim of tackling unmet medical needs.
Remedy Plan is a cancer therapeutics company developing a pipeline of exciting small molecule drugs that cause cancer stem cells to differentiate and exhibit activity across multiple oncological malignancies.
Rubedo discovers and develops medicines focused on biological youth by targeting the pathologic cells that drive aging. They combine experience in multiple fields of research, drug discovery, software engineering and entrepreneurship spanning across aging science, regenerative medicine, medicinal chemistry, artificial intelligence, informatics, drug development.
Southern Research is a nonprofit, full-service contract research organization with more than 80 years of experience in drug discovery and development.
TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.
UCB is continuously working to advance science and embrace new knowledge, bringing passion and leadership to solving challenges that matter to people living with severe diseases.
Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). They aim to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. Spun out of an academic-industry collaboration between Novartis Institutes for BioMedical Research and the University of California, Berkeley, Vicinitas Therapeutics is based in South San Francisco, California.
